Bio-Rad LaboratoriesBIO
Recorded

Bio-Rad Laboratories UBS Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration35 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Doug SchenkelAnalyst

All right. Good morning, everybody. I'm Doug Schenkel, and on behalf of UBS, it is my pleasure to welcome Roop Lakkaraju, EVP and Chief Financial Officer of Bio-Rad. Roop, thank you for being here this morning.

Roop LakkarajuEVP and CFO

Thanks for having us, Doug.

Doug SchenkelAnalyst

Bio-Rad sits at a unique position today, balancing a still mixed demand environment against a more active focus on portfolio priorities, margins, and capital allocation. The company also, of course, has a meaningful stake in Sartorius, which introduces an interesting dimension in bioprocessing. As I've started to look at Bio-Rad more and more, I mean, it's a company I haven't formally covered in my career. It's a company, of course, I've followed across my career. It does seem like a lot is changing, and it's not necessarily your father's Bio-Rad. Things are evolving. I think it's a really interesting time to sit down and talk about a few things this morning. With that in mind, maybe the best place to start is to really talk about how things are evolving at Bio-Rad, and then from a growth gap algorithm standpoint.

Doug SchenkelAnalyst

Really what I'm talking about is, if we think about how you've been growing more in the low single digits, how do we go from those levels of growth recently to get back to market growth? What are the key steps? How much of this is execution versus portfolio evolution? Maybe we can start there.

Roop LakkarajuEVP and CFO

Yeah, appreciate the setup, Doug. I've been with the company for about two and a half years now, and we have pretty much an all-new executive suite Right that's joined Norman.

Roop LakkarajuEVP and CFO

Norman's the one who's hired us, obviously. It's an exciting time. We have a lot of transformation going on, and I appreciate the setup that you just provided. I think as we think about market growth rate, this is critical. To your point, historically, we've been, let's call it 1.5%-2%, as you said. It's multiple elements here, but it starts, in order to drive market growth rates, you got to have portfolio. One of the things that we have doubled down on, if you will, is R&D vitality. Part of that is execution in terms of driving R&D vitality. We've got numerous examples. Most recently, we just announced a new imager technology that we brought out two quarters ahead of schedule, right? That's not something we've historically been able to do.

Roop LakkarajuEVP and CFO

Not only that, but we've incorporated AI technology within there in terms of image analysis and what that provides. We're thinking about how the markets are evolving and what are the needs, and how we can execute more effectively, and we have other examples of that. I think part of this is that R&D vitality and improving that portfolio. Part of that is also just execution.

Roop LakkarajuEVP and CFO

Right. Predictable execution that we need to have, because when we look at the top line growth rate opportunity, that's one thing, but the margin expansion opportunity is maybe just as great for us.

Roop LakkarajuEVP and CFO

Part of that is our own self-help that we've been working on over the last two years. Part of it is looking at M&A opportunities that can accelerate top line growth, but also margin expansion. Happy to unpack that a little bit with us here today, but it's all of those elements, if you will.

Doug SchenkelAnalyst

From a signpost standpoint, what should we be looking for in terms of, hey, Roop and the team are doing a good job when it comes to better commercial execution, better cost management, and R&D vitality? What should we be looking for and over what timeframe?

Roop LakkarajuEVP and CFO

Yeah, I mean, what we've talked about, it's already been a multi-year journey, and really we're doing a lot of foundational things. A lot of what we talked about, or I just mentioned just now, are foundational things that we're putting in place. As we think about moving things forward, last few years, we've had negative growth rate. It's been a declining rate. Part of that end market challenges and where our portfolio sits as it relates to market opportunities, but part of it is execution, as we've talked about. That's one aspect of, hey, do we turn to a positive growth rate? Do we then march ourselves up towards market growth rate? Unfortunately, there's no silver bullet that takes us from where we have been to that market growth rate, where we want to put that. That's one aspect of it.

Roop LakkarajuEVP and CFO

The second piece is the continued margin expansion, and the margin expansion's both gross margin expansion based on mix evolution, based on execution improvements, and it's also operating margin, obviously, and that's the other piece of that. From an R&D vitality, that's a little bit more difficult because that's an internal metric that we monitor and measure and drive to. But from an external standpoint, really it's the pace of new product introductions that we bring to market. You've seen some of that over the last couple years. As an example, we bought a small company last year in the Droplet Digital PCR technology area, Stilla Technologies, which has been core to our ddPCR instrument strength over the last one year. When you look at, we have over 400,000 assays on digital PCR within Bio-Rad.

Roop LakkarajuEVP and CFO

We were able to port that within a year, all of that over to the Stilla technology. And those are critical improvements to make because then that's a differentiator for us, and so it allows us to position that technology in the marketplace with that assay library, which is market leading. And so it's these sort of things that you can measure specifically that ultimately have an impact on top line and margin expansion.

Doug SchenkelAnalyst

I know the third quarter, it's not where you want to be, but it was a step in the right direction, right?

Doug SchenkelAnalyst

Yeah. Q3 sales returned to constant currency growth, just under 1%.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day